174 related articles for article (PubMed ID: 31788318)
1. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.
Motoki K; Igarashi T; Omura K; Nakatani H; Iwanaga T; Tamai I; Ohashi T
Pharmacol Res Perspect; 2019 Dec; 7(6):e00533. PubMed ID: 31788318
[TBL] [Abstract][Full Text] [Related]
2. Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor.
Fukase H; Okui D; Sasaki T; Fushimi M; Ohashi T; Hosoya T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):17-24. PubMed ID: 31823130
[TBL] [Abstract][Full Text] [Related]
3. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
Kumagai Y; Sakaki M; Furihata K; Ito T; Inoue K; Yoshida T; Matsumoto S; Furuno K; Hagino A
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):25-35. PubMed ID: 31760530
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects.
Nakatani H; Fushimi M; Sasaki T; Okui D; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):8-16. PubMed ID: 31889230
[TBL] [Abstract][Full Text] [Related]
6. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
Omura K; Miyata K; Kobashi S; Ito A; Fushimi M; Uda J; Sasaki T; Iwanaga T; Ohashi T
Drug Metab Pharmacokinet; 2020 Jun; 35(3):313-320. PubMed ID: 32327267
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
[TBL] [Abstract][Full Text] [Related]
8. A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients.
Hosoya T; Furuno K; Kanda S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):103-111. PubMed ID: 32067130
[TBL] [Abstract][Full Text] [Related]
9. A drug-drug interaction study of a novel, selective urate reabsorption inhibitor dotinurad and the non-steroidal anti-inflammatory drug oxaprozin in healthy adult males.
Furihata K; Nagasawa K; Hagino A; Kumagai Y
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):36-43. PubMed ID: 32076889
[TBL] [Abstract][Full Text] [Related]
10. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Tanaka A; Taguchi I; Hisauchi I; Yoshida H; Shimabukuro M; Hongo H; Ishikawa T; Kadokami T; Yagi S; Sata M; Node K;
Eur J Med Res; 2023 Jul; 28(1):238. PubMed ID: 37461063
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
[TBL] [Abstract][Full Text] [Related]
12. Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Nephrol; 2021 Dec; 25(12):1336-1345. PubMed ID: 34328574
[TBL] [Abstract][Full Text] [Related]
13. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Okui D; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
[TBL] [Abstract][Full Text] [Related]
14. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
Amano H; Kobayashi S; Terawaki H
BMC Nephrol; 2024 Mar; 25(1):97. PubMed ID: 38491453
[TBL] [Abstract][Full Text] [Related]
15. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Hosoya T; Furuno K; Kanda S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):71-79. PubMed ID: 31970593
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Osonoi T; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Endocrinol (Lausanne); 2022; 13():1042061. PubMed ID: 36714585
[TBL] [Abstract][Full Text] [Related]
17. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
Hosoya T; Fushimi M; Okui D; Sasaki T; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):80-91. PubMed ID: 31875931
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects.
Hall J; Gillen M; Liu S; Miner JN; Valdez S; Shen Z; Lee C
Drug Des Devel Ther; 2018; 12():1799-1807. PubMed ID: 29950814
[TBL] [Abstract][Full Text] [Related]
19. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
20. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
